Biosimilars: Not So Far So Fast Genetic Engineering News However, the company said, given the changes in the regulatory and competitive environment, “Teva (through its joint venture with Lonza) is evaluating the path forward for rituximab.” According to the story originally reported in the Israeli newspaper ... |
